Adjuvants are essential for the induction of robust immune
responses
against vaccine antigens. Small-molecule TLR7 agonists hold high potential
for this purpose. In this communication, imiquimod (IMQ) bearing a
cholesterol lipid moiety derivative, IMQ-Chol, was designed and synthesized
as a vaccine adjuvant, which could release parent IMQ molecules in
aqueous conditions via amide bond hydrolysis. We performed a series
of immunological evaluations by cooperating with the inactivated foot-and-mouth
disease virus (FMDV). All of the results confirmed that IMQ-Chol could
stimulate the body for a prolonged time to produce strong humoral
and cellular immunity with a balanced Th1/Th2 immune response through
a TLR7-related MAPK pathway. In addition, the results of the proof-of-concept
vaccine indicated IMQ-Chol had a good effect on preventing and treating
FMD in pigs.